Kangmei Pharmaceutical Co Ltd

SHG:600518 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.54 Billion
CN¥26.00 Billion CNY
Market Cap Rank
#4318 Global
#426 in China
Share Price
CN¥1.88
Change (1 day)
-0.53%
52-Week Range
CN¥1.86 - CN¥2.22
All Time High
CN¥27.48
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more

Kangmei Pharmaceutical Co Ltd (600518) - Net Assets

Latest net assets as of September 2025: CN¥7.22 Billion CNY

Based on the latest financial reports, Kangmei Pharmaceutical Co Ltd (600518) has net assets worth CN¥7.22 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.68 Billion) and total liabilities (CN¥6.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥7.22 Billion
% of Total Assets 52.8%
Annual Growth Rate 19.15%
5-Year Change N/A
10-Year Change -61.73%
Growth Volatility 64.97

Kangmei Pharmaceutical Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Kangmei Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Kangmei Pharmaceutical Co Ltd (1997–2024)

The table below shows the annual net assets of Kangmei Pharmaceutical Co Ltd from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥7.21 Billion +1.81%
2023-12-31 CN¥7.08 Billion +2.22%
2022-12-31 CN¥6.93 Billion -30.51%
2021-12-31 CN¥9.97 Billion +195.76%
2020-12-31 CN¥-10.41 Billion -150.41%
2019-12-31 CN¥20.65 Billion -20.93%
2018-12-31 CN¥26.12 Billion -8.41%
2017-12-31 CN¥28.52 Billion -2.95%
2016-12-31 CN¥29.38 Billion +55.97%
2015-12-31 CN¥18.84 Billion +12.68%
2014-12-31 CN¥16.72 Billion +38.97%
2013-12-31 CN¥12.03 Billion +13.68%
2012-12-31 CN¥10.58 Billion +14.43%
2011-12-31 CN¥9.25 Billion +87.75%
2010-12-31 CN¥4.93 Billion +15.31%
2009-12-31 CN¥4.27 Billion +46.49%
2008-12-31 CN¥2.92 Billion +25.74%
2007-12-31 CN¥2.32 Billion +100.65%
2006-12-31 CN¥1.16 Billion +101.51%
2005-12-31 CN¥573.59 Million +12.06%
2004-12-31 CN¥511.88 Million +15.69%
2003-12-31 CN¥442.44 Million +13.09%
2002-12-31 CN¥391.23 Million +7.16%
2001-12-31 CN¥365.10 Million +251.18%
2000-12-31 CN¥103.96 Million -6.44%
1999-12-31 CN¥111.12 Million +43.92%
1998-12-31 CN¥77.20 Million +21.51%
1997-12-31 CN¥63.54 Million --

Equity Component Analysis

This analysis shows how different components contribute to Kangmei Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 384726.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥13.86 Billion 193.25%
Other Comprehensive Income CN¥1.18 Million 0.02%
Other Components CN¥19.20 Billion 267.65%
Total Equity CN¥7.17 Billion 100.00%

Kangmei Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Kangmei Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Waaree Energies Limited
NSE:WAAREEENER
 		$2.56 Billion
McGrath RentCorp
NASDAQ:MGRC
 		$2.56 Billion
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
 		$2.56 Billion
Penske Automotive Group Inc
NYSE:PAG
 		$2.57 Billion
Drax Group plc
PINK:DRXGF
 		$2.56 Billion
Zydus Lifesciences Limited
NSE:ZYDUSLIFE
 		$2.56 Billion
HEXPOL AB (publ)
OTCGREY:HXXPY
 		$2.56 Billion
Avangrid Inc
NYSE:AGR
 		$2.56 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Kangmei Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,047,559,000 to 7,174,204,000, a change of 126,645,000 (1.8%).
  • Net income of 8,573,669 contributed positively to equity growth.
  • Dividend payments of 750,000 reduced retained earnings.
  • Other comprehensive income decreased equity by 1,034.
  • Other factors increased equity by 118,822,365.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥8.57 Million +0.12%
Dividends Paid CN¥750.00K -0.01%
Other Comprehensive Income CN¥-1.03K -0.0%
Other Changes CN¥118.82 Million +1.66%
Total Change CN¥- 1.80%

Book Value vs Market Value Analysis

This analysis compares Kangmei Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.74x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 40.26x to 3.74x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥0.05 CN¥1.88 x
1998-12-31 CN¥0.06 CN¥1.88 x
1999-12-31 CN¥0.07 CN¥1.88 x
2000-12-31 CN¥0.08 CN¥1.88 x
2001-12-31 CN¥0.28 CN¥1.88 x
2002-12-31 CN¥0.30 CN¥1.88 x
2003-12-31 CN¥0.34 CN¥1.88 x
2004-12-31 CN¥0.39 CN¥1.88 x
2005-12-31 CN¥0.44 CN¥1.88 x
2006-12-31 CN¥0.89 CN¥1.88 x
2007-12-31 CN¥0.72 CN¥1.88 x
2008-12-31 CN¥0.81 CN¥1.88 x
2009-12-31 CN¥1.12 CN¥1.88 x
2010-12-31 CN¥1.45 CN¥1.88 x
2011-12-31 CN¥2.14 CN¥1.88 x
2012-12-31 CN¥2.40 CN¥1.88 x
2013-12-31 CN¥2.74 CN¥1.88 x
2014-12-31 CN¥3.80 CN¥1.88 x
2015-12-31 CN¥4.24 CN¥1.88 x
2016-12-31 CN¥5.80 CN¥1.88 x
2017-12-31 CN¥5.13 CN¥1.88 x
2018-12-31 CN¥5.21 CN¥1.88 x
2019-12-31 CN¥4.15 CN¥1.88 x
2020-12-31 CN¥-2.13 CN¥1.88 x
2021-12-31 CN¥0.72 CN¥1.88 x
2022-12-31 CN¥0.49 CN¥1.88 x
2023-12-31 CN¥0.69 CN¥1.88 x
2024-12-31 CN¥0.50 CN¥1.88 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Kangmei Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.12%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.17%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 1.92x
  • Recent ROE (0.12%) is below the historical average (10.52%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 13.04% 9.67% 0.46x 2.92x CN¥1.85 Million
1998 17.27% 6.84% 0.89x 2.84x CN¥5.33 Million
1999 21.56% 6.14% 1.45x 2.42x CN¥10.82 Million
2000 23.62% 6.97% 1.52x 2.22x CN¥14.16 Million
2001 7.99% 7.66% 0.74x 1.42x CN¥-7.35 Million
2002 11.20% 10.67% 0.65x 1.61x CN¥4.71 Million
2003 11.57% 11.02% 0.66x 1.59x CN¥6.96 Million
2004 13.91% 12.87% 0.65x 1.67x CN¥20.02 Million
2005 12.67% 12.43% 0.74x 1.38x CN¥15.29 Million
2006 8.64% 12.10% 0.43x 1.66x CN¥-15.69 Million
2007 7.71% 13.82% 0.40x 1.38x CN¥-53.10 Million
2008 10.10% 17.06% 0.41x 1.44x CN¥2.96 Million
2009 11.74% 21.10% 0.38x 1.46x CN¥74.32 Million
2010 14.53% 21.62% 0.40x 1.67x CN¥222.95 Million
2011 10.87% 16.53% 0.40x 1.65x CN¥80.40 Million
2012 13.62% 12.91% 0.62x 1.70x CN¥383.09 Million
2013 15.63% 14.07% 0.60x 1.85x CN¥677.05 Million
2014 13.67% 14.33% 0.57x 1.67x CN¥614.28 Million
2015 14.69% 15.26% 0.47x 2.03x CN¥880.22 Million
2016 11.47% 15.43% 0.39x 1.88x CN¥428.85 Million
2017 7.57% 12.23% 0.27x 2.30x CN¥-691.50 Million
2018 1.46% 2.19% 0.23x 2.86x CN¥-2.18 Billion
2019 -22.72% -40.72% 0.18x 3.15x CN¥-6.71 Billion
2020 0.00% -574.37% 0.16x 0.00x CN¥-30.03 Billion
2021 79.76% 190.68% 0.26x 1.62x CN¥6.93 Billion
2022 -38.69% -64.31% 0.28x 2.18x CN¥-3.38 Billion
2023 1.45% 2.10% 0.34x 2.03x CN¥-602.23 Million
2024 0.12% 0.17% 0.38x 1.92x CN¥-708.85 Million

Industry Comparison

This section compares Kangmei Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Kangmei Pharmaceutical Co Ltd (600518) CN¥7.22 Billion 13.04% 0.89x $2.56 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million